An orthopedic oncologist is a surgeon who specializes in tumors that grow in bones, muscles, cartilage, fat, nerves, and other connective tissues. This includes both cancerous tumors (sarcomas) and benign growths that threaten the structure or function of the skeleton. The specialty sits at the intersection of cancer care and orthopedic surgery, and its central achievement over the past few decades has been making limb-saving surgery the standard approach for tumors that once required amputation.
Conditions They Treat
The scope of orthopedic oncology covers three broad categories: primary bone cancers, soft tissue sarcomas, and benign tumors or tumor-like conditions that affect the musculoskeletal system.
Primary bone cancers include osteosarcoma (the most common malignant bone tumor in young people), chondrosarcoma (arising from cartilage), and Ewing sarcoma. Soft tissue sarcomas develop in fat, muscle, or nerve tissue and carry names like liposarcoma, fibrosarcoma, and malignant peripheral nerve sheath tumors. These are rare cancers. Collectively, bone and soft tissue sarcomas account for less than 1% of all adult cancers, which is exactly why a specialist matters: most general surgeons rarely encounter them.
Beyond primary cancers, orthopedic oncologists also manage cancer that has spread to bone from elsewhere in the body (metastatic disease), multiple myeloma that weakens the skeleton, and benign bone tumors such as giant cell tumors, osteochondromas, enchondromas, and bone cysts. Benign doesn’t always mean harmless. An aneurysmal bone cyst can be locally aggressive and destructive. A giant cell tumor’s gold-standard treatment is surgery. An osteoblastoma left untreated can damage nearby bone or compress nerves. The decision to operate on a benign tumor typically depends on whether it causes pain, threatens a fracture, limits function, or shows signs of aggressive growth.
How They Diagnose Tumors
The diagnostic process usually starts with plain X-rays, which can reveal a great deal about a bone lesion’s character. From there, MRI is the workhorse imaging tool. Its ability to show soft tissue detail helps define the tumor’s size, contents, and relationship to nearby blood vessels and nerves, all of which are critical for planning both the biopsy and any future surgery. A whole-length MRI of the affected bone can also detect “skip metastases,” smaller satellite tumors that might otherwise be missed.
CT scans, bone scans, and occasionally angiography round out the imaging workup. A bone scan using a radioactive tracer can identify whether the disease has spread to other bones. Angiography is reserved for highly vascular tumors that may need their blood supply reduced before surgery.
Biopsy is the definitive step. Options range from fine-needle aspiration and core-needle biopsy (done through the skin with image guidance) to open surgical biopsy. Many centers now favor percutaneous needle biopsy because it’s less invasive, though open biopsy remains the gold standard when a needle sample can’t capture enough tissue for a reliable diagnosis. This is common with cystic tumors or bone lesions that haven’t broken through into soft tissue. Where and how the biopsy is performed matters enormously, because a poorly placed biopsy track can complicate later surgery. This is one reason referral to a specialist before biopsy is so strongly emphasized.
Limb-Salvage Surgery
The signature procedure in orthopedic oncology is limb-salvage (or limb-sparing) surgery. The surgeon removes the tumor along with a margin of healthy tissue, then reconstructs the resulting gap in bone or soft tissue so the patient keeps their arm or leg. This has replaced amputation as the treatment of choice for most extremity sarcomas.
The primary goal is always the same: avoid local recurrence, which in many bone cancers is life-threatening. The secondary goal is to preserve as much function as possible. A meta-analysis of osteosarcoma patients found that five-year overall survival was roughly twice as high in those treated with limb-salvage surgery compared to amputation. Disease-free survival was similar between the two groups, and while local recurrence rates were numerically higher with limb salvage, the difference was not statistically significant. In practical terms, saving the limb does not come at the cost of cancer control in appropriately selected patients.
Reconstruction after tumor removal takes several forms. Mega-endoprostheses (large metallic joint replacements) are the most common option for defects near joints, allowing patients to bear weight immediately and return to activities relatively quickly. Allografts, which are donated bone segments, offer a biological alternative. Vascularized fibula grafts, where a living piece of the patient’s own fibula is transferred with its blood supply intact, work well for combined bone and soft-tissue defects. The choice depends on the location, the size of the gap, and the patient’s age and activity level.
3D-Printed Implants and Custom Guides
One of the most significant recent advances in the field is 3D printing. A systematic review of 296 sarcoma patients treated with 3D-printed technology found four main applications: custom porous-titanium joint replacements, patient-specific pelvic or spinal implants, surgical cutting guides that help the surgeon achieve precise tumor margins, and hybrid reconstructions combining guides with bone grafts.
Pelvic sarcomas have historically been among the hardest tumors to operate on because of the pelvis’s complex shape and proximity to major organs and blood vessels. In a series of 23 patients treated with 3D-printed custom pelvic implants, surgeons achieved more precise resections and good functional results, with five-year implant survival reaching 74%. In pediatric patients, where standard off-the-shelf implants often don’t fit small or still-growing bones, 3D printing is especially valuable. One published case involved a four-year-old with Ewing sarcoma of the tibia who received a custom-growing endoprosthesis, preserving the limb and allowing the child to walk shortly after surgery.
A study of 59 sarcoma surgeries using 3D-printed guides and implants showed reduced operating time, average surgical margins of just 1.2 mm (meaning very little unnecessary tissue was removed), and significantly less radiation exposure during the procedure.
The Team Around Them
Orthopedic oncologists rarely work alone. Sarcoma care is built around a multidisciplinary tumor board, a regular meeting where a group of specialists reviews each patient’s case and agrees on a treatment plan. A typical board includes the orthopedic oncology surgeon, a radiologist who specializes in musculoskeletal imaging, a sarcoma pathologist, medical oncologists (who manage chemotherapy), radiation oncologists, rheumatologists, and plastic surgeons. This structure exists because sarcomas are complex and rare enough that no single specialty has the full picture.
For the patient, this means the orthopedic oncologist often serves as the central coordinator of care, particularly for decisions about whether surgery is the right approach, what type of surgery to perform, and how to sequence it with chemotherapy or radiation. In osteosarcoma, for example, patients typically receive chemotherapy before surgery to shrink the tumor, followed by more chemotherapy afterward. The orthopedic oncologist plans the surgical window within that sequence.
Training and Qualifications
Becoming an orthopedic oncologist requires completing medical school, a five-year residency in orthopedic surgery, and then a 12-month fellowship specifically in musculoskeletal oncology, as defined by the Accreditation Council for Graduate Medical Education (ACGME). That fellowship must be directed by a surgeon who has completed the same specialized training. In total, the path from medical school to independent practice takes at least 10 years.
The fellowship year is intensely focused on tumor surgery, reconstruction techniques, biopsy planning, and the coordination of care with oncology teams. Because sarcomas are rare, these fellowships are concentrated at major academic medical centers and high-volume cancer hospitals, which is also where most orthopedic oncologists ultimately practice.
When You Might Be Referred
Most people see an orthopedic oncologist after an unexpected finding on an X-ray or MRI, a bone lesion discovered during evaluation for pain or a fracture, or a growing lump in the soft tissue of an arm or leg. Primary care doctors, general orthopedic surgeons, and emergency physicians are the most common sources of referral. You might also be referred if you have cancer elsewhere in your body that has spread to bone and is weakening the skeleton enough to risk a fracture or require stabilization surgery.
Not every referral leads to a cancer diagnosis. A significant portion of what orthopedic oncologists evaluate turns out to be benign. But the value of the referral is that a specialist can distinguish between a harmless incidental finding and something that needs intervention, using the same imaging and biopsy expertise they apply to malignant disease.